Advertise on podcast: Diabetes Connections | Type 1 Diabetes

On this bonus episode of diabetes connections.. the creator of Gluki, a new app designed to help kids understand diabetes through games, rewards, and interactive learning. I'm talking to Staci DePatie who lives with type 1.  Staci's working with students at UC Irvine to bring Gluki to life, including some interesting new AI features. We'll talk about how it all works, why she believes building what she calls "diabetes IQ" is so important, and I'll ask some questions about AI safety, cost, and whether kids really want to spend more time thinking about diabetes, even if it's as part of a game. This podcast is not intended as medical advice if you have those kinds of questions please contact your healthcare provider. Check out all of our events like Moms' Night Out and Club 1921 here. Announcing Community Commericals! Learn how to get your message on the show here. Learn more about studies and research at Thrivable here Please visit our Sponsors & Partners - they help make the show possible! Omnipod - Simplify Life All about Dexcom  All about VIVI Cap to protect your insulin from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com

This week on Diabetes Connections In the News… a change from Dexcom sparks a big community response  New developments in the race to protect insulin-producing beta cells, Lilly's GLP-1 pill moves closer to approval in Europe, and could remote monitoring help kids with type 1 improve their glucose management? Plus, are pregnant women being left behind by automated insulin delivery technology? And a Major League moment to remember as a player with type 1 diabetes sends the Milwaukee Brewers to the World Series! Check out all of our events like Moms' Night Out and Club 1921 here. Announcing Community Commericals! Learn how to get your message on the show here. Learn more about studies and research at Thrivable here Please visit our Sponsors & Partners - they help make the show possible! Omnipod - Simplify Life All about Dexcom  All about VIVI Cap to protect your insulin from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com  Transcript: Welcome! I'm your host Stacey Simms and this is an In The News episode.. where we bring you the top diabetes stories and headlines happening now. A reminder that you can find the sources and links and a transcript and more info for every story mentioned here in the show notes. Who else is getting ready for 2027? I know, I can't believe it either but I'm already booking to speak and we've got events on the books. I will not wish the rest of this year away, we've still got a lot going on, but please follow along, I'll keep you posted on where we're going and what's up. Off to Seattle in a couple of days for MNO.. Okay.. our top story this week: XX Dexcom is facing criticism from the diabetes community after users were presented with updated terms and conditions as they used the app. The notification included the message, "Please uninstall app if you don't agree." Some users reported they couldn't get past the notification to view their glucose readings without accepting the terms. The controversy centers on provisions involving mandatory arbitration and class action waivers. Those provisions can limit a user's ability to pursue certain legal claims against Dexcom in court, instead requiring disputes to be handled through individual arbitration. The updated terms also raise questions about data privacy and the use of information for artificial intelligence features. Rob howe from Diabetics Doing Things has an itnerivew going live later this week with Peter Simpson, CTO of Dexcom. Rob released a short clip from that interview, and gave me permission to re-air part of it here.. (clip) I have not yet confirmed with Dexcom, but others on social media say that Dexcom has since clarified that users can opt out of the arbitration provision and continue using the app. According to the terms shared by users, they have 30 days after accepting to opt out by emailing Dexcom's legal department with their name, address, and a statement declining arbitration. I've reached out to Dexcom, but have not yet received a response, they say they are working on it. If we get it after this episode goes live, I'll jump on social with an update. XX Immunocore has announced that the first person with type 1 diabetes has received an experimental treatment in a Phase 1 clinical trial. The therapy, called IMC-S118AI, is designed to protect insulin-producing beta cells by targeting and switching off the immune cells that attack them in people with T1D. Unlike treatments that affect the entire immune system, this approach is designed to work specifically around the beta cells, with the goal of preserving the body's ability to produce insulin. Earlier laboratory research using human pancreatic tissue showed promising results, including reduced immune attacks on beta cells and preserved insulin secretion. The Phase 1 trial will now evaluate the treatment's safety, how it moves through the body, and whether it shows signs of working in people with T1D who have a specific genetic marker.   XX SAB Biotherapeutics has received FDA Fast Track designation for SAB-142, an experimental immune therapy designed to slow the progression of type 1 diabetes in people who have recently been diagnosed. The treatment uses human antibodies produced through genetically engineered cattle, with the goal of protecting the body's insulin-producing cells from immune system attacks. SAB-142 is currently being studied in a Phase 2b clinical trial involving people within 100 days of a Stage 3 type 1 diabetes diagnosis, with results expected in the second half of 2027. A separate Phase 3 study is also evaluating the treatment in people diagnosed between 100 days and two years earlier. Fast Track designation could help speed the development and FDA review process, but it does not mean the treatment has been approved or proven effective. https://www.globenewswire.com/news-release/2026/10/13/3379679/0/en/sab-bio-receives-fda-fast-track-designation-for-sab-142-in-stage-3-type-1-diabetes.html XX Eli Lilly's once-daily GLP-1 pill, Foundayo, has taken another step toward approval in Europe. A European Medicines Agency committee has recommended the drug for both weight management and treatment of type 2 diabetes in adults, with a final decision expected from the European Commission in the coming weeks. Foundayo, also known as orforglipron, works similarly to injectable GLP-1 medications but comes in pill form and can be taken at any time of day without restrictions on food or water. The drug was approved in the U.S. for weight management in April 2026, while FDA review for type 2 diabetes is still pending. If approved in Europe, Foundayo would compete with Novo Nordisk's oral GLP-1 medications, including the Wegovy pill for weight management and Rybelsus for type 2 diabetes. https://www.pharmexec.com/view/ema-panel-backs-lilly-foundayo-obesity-type-2-diabetes-europe XX A small pilot program at UC Davis Health found that remotely monitoring glucose data between doctor visits helped young people with type 1 diabetes improve their blood sugar management. The four-month study included 20 children and teens with A1Cs above 8% who were already using continuous glucose monitors. Clinicians reviewed their CGM data weekly and reached out by phone, text, or online messaging when patients needed additional support. By the end of the program, average time-in-range increased from 34% to 40%, while time spent above target dropped by nearly six percentage points. Patients also responded positively, with 83% saying remote monitoring should continue as part of their diabetes care. Researchers hope to expand the program and study whether this approach can also benefit people newly diagnosed with type 1 diabetes.https://health.ucdavis.edu/news/headlines/remote-monitoring-program-improves-diabetes-management-for-youth-with-type-1-diabetes/2026/10   XX A new editorial in Diabetes Care argues that pregnant women with type 1 diabetes are being left behind when it comes to automated insulin delivery technology. While AID systems have become the recommended treatment for people with T1D, most systems available in the U.S. aren't designed to meet the tighter glucose targets needed during pregnancy. The authors point out that pregnant women have routinely been excluded from clinical trials, leaving major gaps in research about how well these systems work during pregnancy. In fact, only four randomized trials worldwide have studied AID during pregnancy, involving just over 300 participants. The editorial calls on device manufacturers, researchers, and regulators to include pregnant women in clinical trials, develop pregnancy-specific technology, and collect more real-world data on existing systems. The authors say these changes are urgently needed to improve outcomes for both mothers and babies while reducing the burden of diabetes management during pregnancy. T1d pregnancy and me study team, we did an episode on this. XX A sugar naturally found in red meat may help explain the connection between eating red meat and an increased risk of type 2 diabetes. Researchers in France followed nearly 90,000 adults and found that those who consumed the most of this sugar, called Neu5Gc, had a 63% higher risk of developing type 2 diabetes compared to those who consumed the least. Neu5Gc is found primarily in beef and lamb, and researchers believe it may trigger an immune response that leads to chronic inflammation. The association remained significant even after accounting for factors such as physical activity, diet, and body weight. However, when researchers adjusted for the total amount of red meat consumed, the association was no longer statistically significant, meaning they can't say whether the sugar itself is responsible for the increased risk. The findings were presented at the European Association for the Study of Diabetes annual meeting and are considered preliminary. https://www.sciencedaily.com/releases/2026/10/261017230031.htm XX Breakthrough T1D, formerly JDRF, the leading global type 1 diabetes (T1D) research and advocacy organization, announces the conclusion of the inaugural Breakthrough T1D Clinical & Research Congress (CRC 2026).   From October 9-11, 2026, this landmark gathering of the global T1D community brought together world-renowned clinicians, researchers, scientists, healthcare professionals, industry leaders, people with lived experience, and community advocates in Philadelphia, Pennsylvania with the goal of improving lives and driving toward a world without T1D.   "Across the Congress, we looked at T1D from every angle: what we are learning about the disease, how that knowledge is shapi

A new company brings together two technologies: lab-grown insulin-producing cells and an implantable pouch designed to help those cells survive and function inside the body. Sernova makes the pouch, Seraxis grows the cells – together they are BetaNova hopes that bringing these two technologies together could move us closer to a functional cure for type 1 diabetes. So what does this merger really mean? What makes these cells different? And could this approach eventually work without immunosuppressive drugs and actually be available to millions of people with type 1? I'm talking with the CEOs of the companies that are merging: Jonathan Rigby – who lives with type 1 -  and Will Rust about the science, the challenges, and why they believe this combination could be a game changer. Our past episodes with Sernova here This podcast is not intended as medical advice if you have those kinds of questions please contact your healthcare provider. Check out all of our events like Moms' Night Out and Club 1921 here. Announcing Community Commericals! Learn how to get your message on the show here. Learn more about studies and research at Thrivable here Please visit our Sponsors & Partners - they help make the show possible! Omnipod - Simplify Life All about Dexcom  All about VIVI Cap to protect your insulin from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com

On this bonus episode of Diabetes Connections, catching up with Dexcom after the EASD  international conference. I'm asking your questions about longer sensor wear for kids, changes to adhesive, what's going on with the G8 and more.  Plus Dexcom presented a few studies at the summer conferences about some pretty significant benefits of CGM, including fewer DKA-related hospital visits for people with type 1 and improved glucose outcomes for people with type 2 who aren't using insulin. This podcast is not meant at medical advice, if you have those types of questions, please ask your healthcare provider. Check out all of our events like Moms' Night Out and Club 1921 here. Announcing Community Commericals! Learn how to get your message on the show here. Learn more about studies and research at Thrivable here Please visit our Sponsors & Partners - they help make the show possible! Omnipod - Simplify Life All about Dexcom  All about VIVI Cap to protect your insulin from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com

This week on Diabetes Connections In the News… A new combination drug shows big weight loss and A1C improvements for people with type 2. New guidance aims to cut down on adults being misdiagnosed with the wrong type of diabetes. Could trying to keep your glucose too steady affect your quality of life? Very low-carb diets for kids with type 1, and new research on putting early-onset type 2 into remission. The FDA clears an app that recommends insulin dose changes directly to people using injections—and approves a once-a-week insulin for type 2. Plus, new data on Lilly's daily GLP-1 pill, gaps in CGM access for type 2, and a surprising study looking at type 1 and the rotavirus vaccine.  And what do sex and running a marathon have in common? Two new studies look at type 1 diabetes, physical activity, and the risk of low blood sugar. Check out all of our events like Moms' Night Out and Club 1921 here. Announcing Community Commericals! Learn how to get your message on the show here. Learn more about studies and research at Thrivable here Please visit our Sponsors & Partners - they help make the show possible! Omnipod - Simplify Life All about Dexcom  All about VIVI Cap to protect your insulin from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com    This week on Diabetes Connections In the News… A new combination drug shows big weight loss and A1C improvements for people with type 2. New guidance aims to cut down on adults being misdiagnosed with the wrong type of diabetes. Could trying to keep your glucose too steady affect your quality of life? Very low-carb diets for kids with type 1, and new research on putting early-onset type 2 into remission. The FDA clears an app that recommends insulin dose changes directly to people using injections—and approves a once-a-week insulin for type 2.   Plus, new data on Lilly's daily GLP-1 pill, gaps in CGM access for type 2, and a surprising study looking at type 1 and the rotavirus vaccine.   And what do sex and running a marathon have in common? Two new studies look at type 1 diabetes, physical activity, and the risk of low blood sugar.   All that and more, coming up! It's all coming up right after this. (AD BREAK) Welcome! I'm your host Stacey Simms and this is an In The News episode.. where we bring you the top diabetes stories and headlines happening now. A reminder that you can find the sources and links and a transcript and more info for every story mentioned here in the show notes. Super excited to tell you that we have joined the Health Podcast Library! Over the years, I've been asked to join a lot of networks – and I've thought about starting my own – but this is the first one that made sense to me.  Health Podcast Library is a free place to find health podcasts from credible people and organizations. The creators and organizations producing each show are reviewed before it is listed. They believe sourcing matters. They don't pay me to be there and I'm proud to say I'm the first Diabetes Show featured on the Library to sign their The Health Content Integrity Pledge is a commitment from creators across all health topics and platforms to continuously work toward embedding evidence-based principles in their content creation and platform management. As creators of health-related content, we recognize our responsibility to provide accurate, transparent, and credible information that helps people make informed decisions about their health and well-being. Go check it out and if you're a health podcaster, consider joining. https://healthpodcastlibrary.com/ Health podcast networks Okay.. our top story this week: XX Eli Lilly says an experimental drug combination helped people with obesity or overweight and type 2 diabetes lose an average of 23.3% of their body weight over 48 weeks, while also improving A1C. The treatment, called eloraTZP, combines the experimental drug eloralintide with Lilly's approved diabetes and weight-loss medication Zepbound. At the highest dose, participants lost an average of 54.1 pounds. The results are notable because people with type 2 diabetes typically lose less weight with obesity medications than people without diabetes. The study included 367 adults with type 2 diabetes and obesity or overweight. The combination targets three hormones involved in blood sugar, digestion and appetite: GIP, GLP-1 and amylin. Side effects, mainly gastrointestinal, were more common with the combination, and as many as 27% of participants taking eloraTZP stopped treatment. Lilly plans to begin phase 3 trials later this year. https://www.fiercebiotech.com/biotech/lilly-raises-weight-loss-bar-its-amylin-zepbound-combo XX New research suggests that for people with type 1 or type 2 diabetes, keeping glucose as steady as possible may not always translate into a better quality of life. In a study of 400 people with diabetes, researchers found that spending more time in the normal glucose range was associated with better quality of life the following day. Surprisingly, greater glucose variability was also linked to better next-day well-being, as long as glucose remained within safe limits. The findings, presented at the European Association for the Study of Diabetes annual meeting in Milan, do not suggest that high or low blood sugar is beneficial. Instead, researchers say they may point to a tradeoff in diabetes management: the effort and restrictions involved in trying to eliminate every glucose fluctuation could sometimes interfere with everyday activities and enjoyment of life. The study combined continuous glucose monitor data with daily assessments of mood, energy, sleep, stress and overall well-being. https://www.sciencedaily.com/releases/2026/09/260927225019.htm XX New guidance from the American Diabetes Association and European Association for the Study of Diabetes puts a major focus on correctly diagnosing type 1 diabetes in adults. The report says about 40% of people diagnosed with type 1 after age 30 are initially misdiagnosed as having type 2 diabetes. It emphasizes that type 1 can develop at any age and that adults with the condition may have overweight or obesity, so age and body size alone shouldn't be used to determine diabetes type. The updated guidance recommends islet autoantibody testing when type 1 diabetes is suspected and, in some cases, C-peptide testing to determine how much insulin the body is still producing. It also discourages use of the term "LADA," or latent autoimmune diabetes in adults, saying these cases are better classified as type 1 diabetes. The report also includes expanded guidance on diabetes complications, cardiovascular risk, obesity, exercise, nutrition and mental and emotional health. https://www.medscape.com/viewarticle/guidance-type-1-diabetes-management-adults-updated-2026a1001080 XX Eli Lilly says its once-daily GLP-1 pill Foundayo, also known as orforglipron, lowered A1C and weight while demonstrating cardiovascular safety in adults with type 2 diabetes and obesity or overweight who were at increased risk for heart problems. In the study, participants taking Foundayo lowered their A1C by 1.6 percentage points and lost an average of 8.8% of their body weight, or nearly 18 pounds, after one year. Those taking long-acting insulin lowered A1C by 1 percentage point and gained an average of 1.7% of their body weight.   Foundayo was also found to be at least as safe as insulin glargine when researchers looked at major cardiovascular events, including heart attack and stroke. The study also reported improvements in blood pressure, waist circumference and cholesterol, along with a slower decline in kidney function. The results were presented at the European Association for the Study of Diabetes annual meeting in Milan and published in The Lancet. https://www.fiercepharma.com/pharma/lilly-gives-deeper-glimpse-foundayos-heart-helping-odds-diabetes-obesity-phase-3 XX A large Norwegian study found that type 1 diabetes diagnoses among young children increased after the country introduced routine rotavirus vaccination in 2014. Researchers followed more than 740,000 children and found that the rate of type 1 diabetes before age 5 was 11% higher than expected based on trends before the vaccine was introduced. The findings were presented at the European Association for the Study of Diabetes annual meeting and published in Diabetologia.   Importantly, the study does not show that the rotavirus vaccine causes type 1 diabetes. When researchers compared fully vaccinated children directly with unvaccinated children, the difference in type 1 diabetes risk was not statistically significant. Researchers had been studying the vaccine because infections, including rotavirus, have been investigated as possible environmental factors affecting type 1 diabetes risk, and previous studies have produced conflicting results. https://www.news-medical.net/news/20261001/Type-1-diabetes-incidence-rose-by-1125-after-rotavirus-vaccine-rollout-in-Norway.aspx XX A large study of children with type 1 diabetes found that very low- and low-carbohydrate diets were associated with better blood sugar control and lower insulin needs, without evidence of impaired growth or increased rates of severe low blood sugar or diabetic ketoacidosis. The research included more than 45,000 children ages 1 to 17 and used up to 25 years of data. The findings were presented at the European Association for the Study of Diabetes annual meeting in Milan.   Children eating fewer carbohydrates also had smaller increases in BMI and A1C over time compared with those eating standard or higher

On this bonus episode of diabetes connections, we're talking about the Beyond Barriers Innovation Accelerator. This is a project from Beyond Type 1 which is investing in community-based organizations and entrepreneurs working to close those gaps. We'll hear about some really interesting projects from comic books for kids to apps for first responders and programs to help with cost… And we'll zoom out: eleven years after Beyond Type 1 launched, what is the organization today—and how is it trying to make sure more people with diabetes have the opportunity not just to survive, but to thrive? What's the mission for Beyond Type 1 in 2026? This podcast is not intended as medical advice, if you have those kinds of questions, please contact your healthcare provider. More about the Innovation Accelerator and Beyond Type 1 here Check out all of our events like Moms' Night Out and Club 1921 here. Announcing Community Commericals! Learn how to get your message on the show here. Learn more about studies and research at Thrivable here Please visit our Sponsors & Partners - they help make the show possible! Omnipod - Simplify Life All about Dexcom  All about VIVI Cap to protect your insulin from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com

Shannon Boggs' daughter Raelynn, was still doing backflips at gymnastics just days before she landed in the ICU in DKA and was diagnosed with type 1 diabetes. Four years later, things look very different. Raelynn is starting middle school, taking on more of her own diabetes management, going to regular sleepaway camp, and even sharing her life with type 1 online — with hundreds of thousands of people following along. Shannon and I talk about that sometimes-scary balance between independence and diabetes management, why finding community changed everything for their family, and how she thinks about sharing Raylan's diabetes, and her whole family's story, so publicly on social media. This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider. Check out all of our events like Moms' Night Out and Club 1921 here. Info about the bananas Chesapeake Bay Bridge Tunnel here Announcing Community Commercials! Learn how to get your message on the show here. Learn more about studies and research at Thrivable here Please visit our Sponsors & Partners - they help make the show possible! Omnipod - Simplify Life All about Dexcom  All about VIVI Cap to protect your insulin from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com

On this episode of Diabetes Connections In the news… The ADA conference controversy continues with a boycott now, new patch pump approved, an update on long running research to reverse type 1, plus consensus guidelines on T1D screening, intermittent fasting for type 1, a new surprising study about COVID and T1D, statins, type 2 and dementia, and lots more..  This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider.  Want to let you know about a webinar I'm doing with Abbott later this month. That's Sept 23 at 7pm ET. We'll be talking about ketones, DKA and learn more about their dual CGM/ketone monitor that was just approved. Join us for a webinar September 23 Check out all of our events like Moms' Night Out and Club 1921 here. Announcing Community Commericals! Learn how to get your message on the show here. Learn more about studies and research at Thrivable here Please visit our Sponsors & Partners - they help make the show possible! Omnipod - Simplify Life All about Dexcom  All about VIVI Cap to protect your insulin from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com  Transcript: On this episode of Diabetes Connections In the news… The ADA conference controversy continues with a boycott now, an update on long running research to reverse type 1, plus consensus guidelines on T1D screening, intermittent fasting for type 1, a new surprising study about COVID and T1D, statins, type 2 and dementia, and lots more.. It's all coming up right after this. (AD BREAK) Welcome! I'm your host Stacey Simms and this is an In The News episode.. where we bring you the top diabetes stories and headlines happening now. A reminder that you can find the sources and links and a transcript and more info for every story mentioned here in the show notes. We are off to Detroit this week for Moms' Night Out in Bloomfield Michigan. Super excited and as usual I'm getting last minute emails and DMs about respiration from people just finding out about the event. We will always figure it out so drop me a line. But please register now for Seattle next month! Tampa will be open soon as well! Want to let you know about a webinar I'm doing with Abbott later this month. That's Sept 23 at 7pm ET. We'll be talking about ketones, DKA and learn more about their dual CGM/ketone monitor that was just approved. Great crowd already registered for that, hope you can join us. The link is in the show notes. Okay.. our top story this week: XX Member of the American Diabetes Association… are now boycotting it. The notice of the boycott condemns leadership's actions after five researchers were removed by police from its annual meeting in June. Significantly, The editors of ADA's flagship journal, Diabetes Care, have joined on in support of the boycott. "Manuscripts submitted will not be handled until the boycott is over," said Steven Kahn, MBChB, the journal's editor in chief and one of the five researchers ejected from the meeting in New Orleans, in a LinkedIn post on Thursday. Kahn told MedPage Today that "the journal boycott is like establishing a picket line. The boycott already has hundreds of signatures of people who have pledged to suspend all ADA-related activities, including: Planning or attending any meetings led by ADA leadership or the board, including the 2027 ADA Scientific Sessions Participating in board-led activities regarding the investigation of the meeting's events, or the report generated by the "so-called 'independent' committee" Engaging in all other ADA operations, including presentations, fundraisers, grant reviews, manuscript reviews, journal management, manuscript submissions, and position statements The boycott will remain active until the ADA board of directors permits an independent formal review of the organization's structure and function to ensure it "properly represent[s] its professional membership." If demands are not met, signees plan to align with existing or newly formed medical societies. https://www.medpagetoday.com/endocrinology/diabetes/122977 https://docs.google.com/forms/d/e/1FAIpQLSd4h548X9qXgkVREQ71k2gDHiU8WFAFF78wTnmS20_ntwUM0w/viewform XX A new patch pump is coming to the US.. Beta Bionics, Inc. announces FDA clearance of Mint, the Company's patch pump featuring a transformative reusable and disposable architecture that does not require recharging, integrates with industry-leading continuous glucose monitors (CGM) and enables smartphone control for iOS and Android users. The Company expects to initiate the full commercial launch of Mint in the United States in the first quarter of 2027 Mint is expected to launch exclusively through the pharmacy channel. Also announced, that Eversense 365 is now compatible with Beta Bionics Senseonics expects development of the Eversense 365-iLet integration to be completed during the fourth quarter of 2026. Commercial launch is planned following completion of integration activities in the fourth quarter of 2026, subject to required testing, validation activities and applicable regulatory requirements. No word yet on timing for Eversense with Mint. https://www.manilatimes.net/2026/09/14/tmt-newswire/globenewswire/beta-bionics-announces-fda-clearance-of-mint-the-companys-transformative-patch-pump-and-unveils-3d-intelligence-as-its-next-generation-insulin-dosing-algorithm/2424457 XX Seven years after Johns Hopkins researchers discovered a previously unknown immune cell called the "X cell," they're now exploring whether that discovery could lead to a new treatment for type 1 diabetes. In preclinical studies, researchers developed an antibody that was able to target and eliminate specific immune cells responsible for attacking the pancreas's insulin-producing beta cells, while leaving the rest of the immune system intact. The researchers say the approach is especially promising because it could potentially reverse the autoimmune process soon after a type 1 diabetes diagnosis, rather than simply managing blood sugar. The work is still in the early stages and has not yet been tested in people; additional laboratory and preclinical studies are needed before human clinical trials can begin. sclerosis.https://hub.jhu.edu/2026/09/09/federal-funds-support-type-1-diabetes-treatment/ XX A new international consensus recommends routine screening for type 1 diabetes in the general population, offering the first framework for how healthcare providers could put widespread screening into practice. The guidance recommends screening children between ages 2 and 4, with children who test negative screened again at ages 6–8 and 10–15. Screening uses a blood test to look for islet autoantibodies, which can signal that the immune system is attacking insulin-producing cells years before symptoms appear or insulin is needed. Finding type 1 diabetes early can greatly reduce the risk of diabetic ketoacidosis, or DKA, at diagnosis and may give people access to treatments such as teplizumab that can delay progression to clinical T1D. https://www.prnewswire.com/news-releases/breakthrough-t1d-convened-paper-outlines-first-international-consensus-guidance-on-general-population-screening-for-early-stage-type-1-diabetes-302875788.html   XX Eating only between noon and 8 p.m. improved blood sugar control in a small study of adults with Type 1 diabetes and obesity, while avoiding an increase in serious complications. The promising findings offer the first evidence that time restricted eating could become another tool for managing the condition. For the study, Varady recruited adults with Type 1 diabetes who were also classified as obese After six months, the time-restricted eating group showed better blood sugar results than the calorie-reduction group. HbA1c, a blood test that reflects average blood sugar over the previous several months, fell by about 0.5% on average in the time-restricted group.   Couple of things here – very small study, only 32 people in total, who were then randomly placed in three groups with different styles of eating. Also, the lead researcher says this is the first study of it's kind for type 1 – which is obviously not true – you can do a quick google search or listen to past episodes of this show.. https://www.sciencedaily.com/releases/2026/09/260909231740.htm XX A large Danish study found that COVID-19 infection was associated with a slightly lower, rather than higher, risk of subsequently developing type 1 diabetes in people under age 30. Researchers studied more than 2,100 people diagnosed with T1D and found an overall 16% lower risk following a documented COVID infection, with the strongest association—a 42% reduction—seen 31 to 180 days after infection. The reduced risk appeared primarily among people who had not been vaccinated against COVID-19, although researchers cautioned that the vaccination findings were less certain. Importantly, this was an observational study, so it cannot show that COVID infection actually protects against type 1 diabetes or explain what caused the association. Researchers say the findings conflict with some earlier studies and should be investigated in other countries and populations. https://www.news-medical.net/news/20260908/COVID-19-linked-to-lower-subsequent-risk-of-type-1-diabetes.aspx   XX   Semaglutide, a medication widely used for type 2 diabetes and weight loss, may also provide an unexpected benefit for people with asthma. New research presented at the European Respiratory Society (ERS) Congress in Barcelona, Spain, found that semaglutide use

This week on Diabetes Connections.. Now that Eversense 365-day has been out in the real world  and is working with the twiist automated insulin delivery system, we're starting to get a much better picture of what that combination can actually do. This week, Dr. Fran Kaufman is back with new data on Eversense 365, including some impressive results from people using it with twiist. We'll talk about what they're learning, who's using the year-long sensor, and what may be coming next. And that next step is really interesting: a sensor with its own battery that could work even when the external transmitter is removed, and eventually, a fully implanted CGM that could send glucose data directly from under your skin to your phone or watch. Plus, we talk about pediatric plans, additional pump integrations, and why — after 50 years in diabetes care — Fran says she's more excited about the future than ever. This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider. Join us for a Webinar with Abbott: Expert Discussion: Navigating Continuous Ketone Monitoring and DKA With Confidence - Register Here Check out all of our events like Moms' Night Out and Club 1921 here. Announcing Community Commericals! Learn how to get your message on the show here. Learn more about studies and research at Thrivable here Please visit our Sponsors & Partners - they help make the show possible! Omnipod - Simplify Life All about Dexcom  All about VIVI Cap to protect your insulin from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com

A few years ago, when we talked about screening for type 1 diabetes, it still felt a little bit like we were talking about the future. That future may be arriving faster than we realize. Dr. Bryce Nelson is back on the show. After years as a pediatric endocrinologist, he's now working specifically in autoimmune type 1 diabetes with Sanofi. We talk about how much has changed with screening, what we're learning about who's at risk, and the big question: how close are we to screening becoming a routine part of healthcare? And Jenny Hoffman shares what this looks like for a family living it. Her older son was diagnosed at two and a half; after years of screening her younger son, Asher, he tested positive for five autoantibodies at age six. He's still in stage one, and Jenny talks about the surprising difference between fearing a diagnosis and having the time to prepare for one. Where is type 1 screening headed next? That's what we're talking about today. This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider. Learn more about screening: https://www.screenfortype1.com/ Check out all of our events like Moms' Night Out and Club 1921 here. Announcing Community Commericals! Learn how to get your message on the show here. Learn more about studies and research at Thrivable here Please visit our Sponsors & Partners - they help make the show possible! Omnipod - Simplify Life All about Dexcom  All about VIVI Cap to protect your insulin from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com

On this episode of Diabetes Connections In the news… The FDA approves a new indication and health benefit for Mounjaro, lots of CGM news including an update on Medicare coverage for people who don't use insulin and a new study about using CGM when you don't have diabetes, metformin and aging, statins and type 2, and did you know there was a Dolly Parton diabetes connections? That and much more... Check out all of our events like Moms' Night Out and Club 1921 here. Announcing Community Commericals! Learn how to get your message on the show here. Learn more about studies and research at Thrivable here Please visit our Sponsors & Partners - they help make the show possible! Omnipod - Simplify Life All about Dexcom  All about VIVI Cap to protect your insulin from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com  On this episode of Diabetes Connections In the news… The FDA approves a new indication and health benefit for Mounjaro, lots of CGM news including an update on Medicare coverage for people who don't use insulin and a new study about using CGM when you don't have diabetes, metformin and aging, statins and type 2, and did you know there was a Dolly Parton diabetes connections? That and much more.. that's coming up right after this. (AD BREAK) Welcome! I'm your host Stacey Simms and this is an In The News episode.. where we bring you the top diabetes stories and headlines happening now. A reminder that you can find the sources and links and a transcript and more info for every story mentioned here in the show notes. Welcome to September! Want to let you know about a webinar I'm doing with Abbott later this month. That's Sept 23 at 7pm ET. We'll be talking about ketones, DKA and learn more about their dual CGM/ketone monitor that was just approved – more on that coming up. But please register – the link is in the show notes. So much going on over here – tomorrow night we have our Club 1921 in Charlotte, later this month Moms' Night Out Detroit/Bloomfield and in October we're going to Seattle. Please join us. More at d-c dot com slash events. Okay.. our top story this week: XX Another indication for Mounjaro – the FDA approved it to lower the risk of major adverse cardiovascular (CV) events (MACE), including CV death, non-fatal heart attack, or non-fatal stroke in adults with type 2 diabetes who are at high risk for these events. Mounjaro – the brand name of tirzepatide - is already approved as an adjunct to diet and exercise to improve blood sugar in adults and children 10 years of age and older with type 2 diabetes. The approval was based on results from the largest and longest tirzepatide study to date, enrolling more than 13,000 participants across 30 countries over more than four and a half years. In the trial, Mounjaro demonstrated non-inferiority to Trulicity (dulaglutide), a GLP-1 treatment with established cardiovascular benefit, with an 8% lower rate of cardiovascular death, heart attack or stroke (MACE-3). The estimated hazard ratio for time to first MACE was 0.92 (95.3% CI: 0.83, 1.01) for Mounjaro compared to Trulicity (dulaglutide). https://www.prnewswire.com/news-releases/fda-approves-lillys-mounjaro-tirzepatide-to-reduce-cardiovascular-risk-in-adults-with-type-2-diabetes-302862415.html XX The FDA approves the Libre Duo – the first device designed to continuously monitor both blood sugar levels and ketone levels in people with diabetes. The Libre Duo 10-Day Continuous Dual Glucose Ketone Monitoring System is now approved for those ages 2 and older. Until now, the agency said, people had to monitor ketone levels with separate tests that only provided a single measurement at one point in time. The new system combines blood sugar and ketone tests and monitors them continuously. Readings -- and alerts in case of dangerous trends -- are sent wirelessly to a smartphone app. The FDA previously granted "breakthrough device" status to the system, which is meant to expedite the device's development and review. https://www.upi.com/Top_News/US/2026/08/25/fda-oks-blood-sugar-ketone-monitor/5521787688375/ XX Diabetes tech firms Dexcom and Abbott are watching closely for a Medicare coverage expansion that could significantly broaden access to their glucose sensors. The Centers for Medicare and Medicaid Services is expected to expand Medicare coverage of continuous glucose monitors to people with diabetes who do not take insulin. Currently, coverage is limited to people with Type 1 or Type 2 diabetes who take insulin or have a history of problematic low blood sugar. Dexcom CEO Jake Leach told investors in a late July earnings call that the company expects to hear back from the CMS before the end of the year, with coverage going into effect in mid-2027.     Dexcom presented results of a randomized, controlled trial earlier this summer at the American Diabetes Association's Scientific Sessions that it expects will support the CMS' decision. The 26-week study found that people who used a CGM had a larger hemoglobin A1C reduction than the control group and spent five more hours per day in a normal glucose range than the control group. https://www.medtechdive.com/news/dexcom-abbott-await-medicare-coverage-expansion-for-cgms/828775/ XX A new study suggests continuous glucose monitors (CGMs) may offer benefits for people with type 1 diabetes that go beyond improving blood sugar and reducing hypoglycemia.   Researchers analyzed health records from more than 8,400 adults with type 1 diabetes receiving care through the Veterans Health Administration. Over one to four years of follow-up, people who started using a CGM had a 10% to 16% lower risk of death from any cause compared with those who did not use one.   The association appeared strongest among people over age 65 and those who were not using insulin pumps. Researchers did not find meaningful differences based on A1C, race or ethnicity, or frailty.   Importantly, this was an observational study using medical records, not a randomized clinical trial, so it cannot prove that CGM use directly caused the lower death rate. But the findings suggest CGM may have important long-term health benefits beyond glucose management.https://visualize.jove.com/42319755-continuous-glucose-monitoring-initiation-is-associated-with-reduced-mortality-in-older-onset-type-1-diabetes-patients-a-target-trial-emulation-study-within-the-veterans-health-administration XX We've been talking about people without diabetes using CGMs for a long time.. now a new study weighs in. Research published in JAMA finds that this wellness trend isn't helpful for people without a diabetes diagnosis. They found that the strongest evidence for CGM use is for people who are already living with diabetes, but not for those without the condition who use them for wellness purposes. It's also worth noting, though, that this new study is a narrative review. This means that the researchers drew their conclusions from the findings reported in several other studies. More randomized controlled trials would be necessary to see whether there are any meaningful health benefits of using a CGM if you don't have diabetes.   Dower also warned that constantly monitoring your blood sugar when you don't have diabetes could lead to unintended health anxiety. In some cases, you may even make accidental lifestyle changes that could be harmful. "[Blood sugar] spikes may occur after meals, but if this leads someone to replace healthy food such as fruit with unhealthy food such as something high in fat but low in carbohydrate, the glucose information has done more harm than good," Dower said. https://www.verywellhealth.com/blood-sugar-monitor-for-people-without-diabetes-12058575   XX   Could metformin somehow influence the biological processes that drive aging? A new review found evidence that metformin may affect several key features of aging, including how cells use energy, inflammation, cellular damage and even some changes in gene activity. Animal studies have shown longer lifespans or improvements in markers of biological aging, while some human studies have also found promising results.   But researchers say there's still no proof that metformin actually slows aging or helps healthy people live longer. Most human research has involved people with diabetes or other health conditions, and one large trial found that while metformin helped prevent type 2 diabetes, it did not reduce cancer, cardiovascular disease or deaths.   Researchers say larger clinical trials in people without diabetes are needed to determine whether metformin can truly extend healthy lifespan—or whether its benefits are primarily related to preventing and treating specific diseases. https://www.technologynetworks.com/drug-discovery/news/metformin-may-influence-longevity-through-the-gut-microbiome-and-epigenetic-changes-416035 XX More to come including more research on a spice thought to help diabetes, predictions about the number of people who may be living with type 1 in the years to come around the world, and a connection I didn't know about between diabetes and Dolly Parton.   XX A compound found in turmeric may help protect blood vessels from some of the damage caused by Type 1 diabetes. In rats, curcumin reduced inflammation, improved cellular signaling, and restored vascular health to levels resembling those of nondiabetic animals. The results hint at a possible new way to reduce the long-term cardiovascular risks of diabetes, but human trials are still needed. Curcumin, the natural compound responsible for turmeric's

We're taught about what to do when blood sugar goes high or low, but almost nothing about what to do when diabetes burnout, anxiety, or fear takes over. My guest – Dr. Mark Heyman says the biggest thing holding you back with type 1 diabetes may not be your blood sugar — but the stress of managing it. Mark lives with type 1 and his new book, Live Free with T1D, offers what he calls an "operating system" for the emotional side of diabetes — practical tools for handling the uncomfortable moments without letting them make your world smaller. This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider. Link to get your FREE copy of "Live Free with T1D" here Check out all of our events like Moms' Night Out and Club 1921 here. Announcing Community Commericals! Learn how to get your message on the show here. Learn more about studies and research at Thrivable here Please visit our Sponsors & Partners - they help make the show possible! Omnipod - Simplify Life All about Dexcom  All about VIVI Cap to protect your insulin from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com

On this episode of Diabetes Connections In the News…  A new basal insulin is available, researchers are working on a "cloak" designed to protect transplanted insulin-producing cells, Retatrutide isn't even approved and it's already the subject of lawsuits, tandem moves to pharmacy and more! Check out all of our events like Moms' Night Out and Club 1921 here. Announcing Community Commericals! Learn how to get your message on the show here. Learn more about studies and research at Thrivable here Please visit our Sponsors & Partners - they help make the show possible! Omnipod - Simplify Life All about Dexcom  All about VIVI Cap to protect your insulin from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com

This week on Diabetes Connections, we're talking about the newest pump from MiniMed – the Flex looks a lot different from any pump produced by the company formerly known as Medtronic Diabetes. It has no screen it's controlled by phone.. and has a lot of other features we'll get into. I'm speaking to MiniMed's EVP, Chief Product and Technology Officer Ali Dianaty about the Flex, their upcoming patch pump, new software, a really interesting look at the testing of these algorithms. And a lot more. Check out all of our events like Moms' Night Out and Club 1921 here. Announcing Community Commericals! Learn how to get your message on the show here. Learn more about studies and research at Thrivable here Please visit our Sponsors & Partners - they help make the show possible! Omnipod - Simplify Life All about Dexcom  All about VIVI Cap to protect your insulin from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com

On this episode of Diabetes Connections In the news… Sanofi acknowledges an insulin shortage, a new oral therapy for type 1 moves along in research, could there be an actual, accurate, non-invasive CGM in the works, ADA conflict continues and a new documentary about Girl Scout cookies shines a spotlight on T1D. Don't miss our upcoming events! Moms' Night Out in Detroit and Seattle, Club 1921 in Charlotte and Phoenix: https://diabetes-connections.com/events/   Announcing Community Commericals! Learn how to get your message on the show here. Learn more about studies and research at Thrivable here Please visit our Sponsors & Partners - they help make the show possible! Omnipod - Simplify Life All about Dexcom  All about VIVI Cap to protect your insulin from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com   Transcript:  (Stacey Track) On this episode of Diabetes Connections In the news… Sanofi acknowledges an insulin shortage, a new oral therapy for type 1 moves along in research, could there be an actual, accurate, non-invasive CGM in the works, ADA conflict continues and I can't wait to tell you about Cookie Queens.. that's coming up right after this. (AD BREAK) Welcome! I'm your host Stacey Simms and this is an In The News episode.. where we bring you the top diabetes stories and headlines happening now. A reminder that you can find the sources and links and a transcript and more info for every story mentioned here in the show notes. We are still looking for your community commercials. These are 30–60 second audio spots created by members of the diabetes community to share: Events you're organizing: a fundraiser, walk, or local meetup Products you've created: maybe you've written a book, have a Substack, designed a T1D-friendly gadget, or launched a small business Helpful projects or resources: things you think others in our community should know about It's your chance to share what you're doing and help others get connected! Full instructions are on the website. While you're there please check out our events. We're turning toward fall and we have a lot going on – MNO and Club 1921.   Okay.. our top story this week: XX I want to talk about Cookie Queens! It might not sound like a hard news story.. but It's my show and I can't wait to watch this. This move follows four Girl Scouts ages 5-12 during cookie season. One of the girls has type 1 – they don't mention it in the trailer, but you can see her omnipod. Here's a clip:   Start the very beginning and stop after "I want to be a supreme court justice." (stop after the "oh..laughter" https://www.youtube.com/watch?v=nnSQS43Eil8   Viewers meet Ara from San Diego, CA (5), Shannon Elizabeth from El Paso, TX (8), Nikki from Chino, CA (9), and Olive from Charlotte, NC (12). Ara has Type 1 diabetes and is shown taking insulin, refilling her pump before bed, and determining with her dad how to sample the cookies she's selling while keeping her blood sugar levels safe. Thumbs down to the Hollywood reporter dot com. In their review they say.. "if this film were itself a baked good, Ara would need to be careful because one bite could cause hyperglycemia or even diabetic ketoacidosis. It's just that sweet." Cookie Queens comes out this month. https://www.hollywoodreporter.com/movies/movie-reviews/cookie-queens-review-prince-harry-meghan-markle-girl-scouts-1236484555/ trailer:   XX Supply issues for Lantus SoloStar pens being acknowledged by Sanofi. The company says it's experiencing "a period of intermittent supply due to increased demand. The company said the increase in demand is being driven by "broader market dynamics," but did not provide additional details. Sanofi said the situation is temporary and is expected to improve over the coming weeks. The company said Lantus U-100 vials and Toujeo U-300, which contain the same active ingredient, remain available. https://www.wral.com/news/local/common-insulin-pen-faces-supply-issues-amid-rising-demand-july-23-2026/ XX The University of Alabama at Birmingham startup TIXiMED Inc. has launched the next phase of clinical testing for a novel oral therapy for Type 1. For now called TIX100, a small-molecule drug designed to inhibit a protein linked to pancreatic beta-cell loss and diabetes progression. The new double-blind, randomized, placebo-controlled study will evaluate the drug's safety, tolerability and pharmacokinetics. Researchers will enroll 18 healthy participants across three dose cohorts at a single United States study site. Participants will receive either TIX100 or a placebo twice daily for 28 days, followed by a seven-day follow-up period. Six participants making up the first cohort have been successfully enrolled thus far. In addition to its potential use in Type 1 diabetes, TIX100 may have applications in Type 2 diabetes and obesity. A recent study found that the drug prevented weight regain and preserved lean muscle mass after discontinuation of GLP-1 therapies in preclinical models. https://www.uab.edu/news/research-innovation/startup-advances-novel-oral-type-1-diabetes-therapy-to-next-phase-of-human-testing XX Researchers at the University of California San Diego say they have developed and validated a Continuous Health Analyzing Ring Module (CHARM), a compact, fully integrated wearable smart ring capable of continuous real-time monitoring of multiple biomarkers in sweat. The wearable device can simultaneously measure up to four biomarkers, including glucose, ketone, uric acid, lactate, ascorbic acid, and alcohol, to provide real-time insights into metabolic health. The study is published in Nature Communications. They say CHARM device contains all necessary biomarker sensors, low-power electronics, and a flexible battery. The left compartment of the device is designed to draw sweat passively using an osmotic hydrogel, a soft polymer that creates a pressure gradient to pull fluid from the skin painlessly. The sweat is then analyzed by multiplexed electrochemical sensor arrays within the same compartment, leading to simultaneous and real-time tracking of four biomarkers at a time.   The right compartment of the device contains a flexible zinc-silver oxide rechargeable battery that supplies power for up to 12 hours of operation between charges. Biomarker information generated through sensors is wirelessly transferred to a connected Bluetooth-enabled device for real-time display The findings indicated that the device performed well in initial temperature, cytotoxicity, and on-body compatibility tests. It also demonstrated high analytical accuracy in preliminary studies involving healthy participants and individuals with type 1 diabetes, highlighting its potential for non-invasive metabolic monitoring. The calculated estimated sweat-based blood glucose concentration showed a mean absolute relative difference of approximately 13.7% against its corresponding blood concentration values.   The device needs further validation in diverse clinical settings and across large diabetic cohorts.   https://www.news-medical.net/news/20260727/Prototype-smart-ring-tracks-multiple-sweat-biomarkers.aspx   XX Hotter weather and rising temps appear to increase the short term risk for low blood sugar in adults with type 1. An analysis of more than 32 million continuous glucose monitor (CGM) readings from nearly 700 adults with T1D in the UK showed a 26% greater risk for hypoglycemia at a temperature of 25 °C (77 °F) than at 13 °C (55.4 °F). Hypoglycemia was defined as a glucose level The study included 679 individuals with T1D and 32,966,282 CGM readings collected between February 23, 2017, and August 8, 2024. Participants had a mean age of 46.4 years and a mean T1D duration of 23.7 years. The researchers observed strong seasonal patterns, with lower odds of hypoglycemia in late winter and early spring, followed by a peak during the summer. The lowest risk occurred on Mondays. The odds then increased over the course of the week and peaked toward the weekend, with a significant odds ratio of 1.14 on Saturdays compared with Mondays. Increases in hypoglycemia were observed during both hot and cold weather, but the association was stronger for heat. The net odds ratio was 1.26 at 25 °C compared with 13 °C.   https://www.medscape.com/viewarticle/when-temperatures-climb-hypoglycemia-risk-rises-type-1-2026a1000q4r XX Seven weeks after the expulsion of five diabetes experts from the American Diabetes Association conference, controversy continues. More than 200 members now calling for two ADA leaders to resign. In response, the ADA delivered its own message Tuesday, expressing appreciation for members' patience while a report is prepared.   The resignation demand, sent last week in an open letter to the ADA board of directors, calls for the removal of CEO Charles Henderson and chief scientific and medical officer Rita Kalyani. It also urges "an independent investigation into the events of the 2026 Scientific Sessions in New Orleans, a full apology to the five colleagues removed from the meeting, and the restoration of editorial independence at Diabetes Care," an ADA scientific journal.   https://www.statnews.com/2026/07/28/american-diabetes-association-fallout-researchers-expulsion/ XX XX Still to come, , a new link between diabetes and dementia, device updates, and why you might want to start rooting for the Red Sox..   XX New study says that people diagnosed with type 1 diabetes (T1D) before the age of 10 years had a 37% higher risk of developing all-cause dementia later in life than thos